FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4248583983> ?p ?o ?g. }

• W4248583983 abstract "Background Spinal muscular atrophy (SMA) is caused by degeneration of anterior horn cells, which leads to progressive muscle weakness. Children with SMA type I will never be able to sit without support and usually die by the age of two years. There are no known efficacious drug treatments that influence the disease course. Objectives To evaluate if drug treatment is able to slow or arrest the disease progression of SMA type I, and to assess if such therapy can be given safely. Drug treatment for SMA type II and III will be will be the topic of a separate Cochrane review. Search methods We searched the Cochrane Neuromuscular Disease Group Trials Register (September 30 2008, The Cochrane Library (Issue 3, 2008), MEDLINE (January 1966 to June 2008), EMBASE (January 1980 to June 2008), ISI (January 1988 to June 2008), and ACP Journal Club (January 1991 to June 2008). Selection criteria All randomized or quasi‐randomized trials that examined the efficacy of drug treatment for SMA type 1 were sought. Participants had to fulfil clinical criteria and, in studies including genetic analysis to confirm the diagnosis, have a deletion or mutation of the SMN1 gene (5q11.2‐13.2) The primary outcome measure was to be time from birth until death or full time ventilation. Secondary outcome measures were to be development of rolling, sitting or standing within one year after the onset of treatment, and adverse events attributable to treatment during the trial period. Data collection and analysis Two authors (WB and AV) independently reviewed and extracted data from all potentially relevant trials. For included studies pooled relative risks and pooled weighted standardized mean differences were to be calculated to assess treatment efficacy Main results One small randomized‐controlled study comparing riluzole treatment to placebo for SMA type 1 was identified and included in the review. Regarding the primary outcome measure three of seven children treated with riluzole were still alive at the age of 30, 48 and 64 months, whereas all three children in the placebo group died, but the difference was not statistically significant. Regarding the secondary outcome measures none of the patients in the riluzole or placebo group developed the ability to roll, sit or stand, and no adverse effects were observed. Authors' conclusions No drug treatment for SMA type I has been proven to have significant efficacy." @default.
• W4248583983 created "2022-05-12" @default.
• W4248583983 creator A5014769151 @default.
• W4248583983 creator A5047421271 @default.
• W4248583983 creator A5064268727 @default.
• W4248583983 creator A5070233617 @default.
• W4248583983 creator A5083275825 @default.
• W4248583983 date "2009-01-21" @default.
• W4248583983 modified "2023-10-05" @default.
• W4248583983 title "Drug treatment for spinal muscular atrophy type I" @default.
• W4248583983 cites W1215506979 @default.
• W4248583983 cites W1568798715 @default.
• W4248583983 cites W1966251255 @default.
• W4248583983 cites W1971572027 @default.
• W4248583983 cites W1971578102 @default.
• W4248583983 cites W1973745643 @default.
• W4248583983 cites W1975687045 @default.
• W4248583983 cites W1977003074 @default.
• W4248583983 cites W1978938547 @default.
• W4248583983 cites W1980477780 @default.
• W4248583983 cites W1983082063 @default.
• W4248583983 cites W1987687980 @default.
• W4248583983 cites W1987830910 @default.
• W4248583983 cites W1988037421 @default.
• W4248583983 cites W1990802591 @default.
• W4248583983 cites W1994865438 @default.
• W4248583983 cites W1996412713 @default.
• W4248583983 cites W2007954199 @default.
• W4248583983 cites W2013834447 @default.
• W4248583983 cites W2016207006 @default.
• W4248583983 cites W2022972923 @default.
• W4248583983 cites W2023929681 @default.
• W4248583983 cites W2024907326 @default.
• W4248583983 cites W2025873430 @default.
• W4248583983 cites W2026841516 @default.
• W4248583983 cites W2028128528 @default.
• W4248583983 cites W2029827355 @default.
• W4248583983 cites W2031889777 @default.
• W4248583983 cites W2032559593 @default.
• W4248583983 cites W2032618470 @default.
• W4248583983 cites W2032701295 @default.
• W4248583983 cites W2032723142 @default.
• W4248583983 cites W2033377350 @default.
• W4248583983 cites W2041122586 @default.
• W4248583983 cites W2042817923 @default.
• W4248583983 cites W2048181785 @default.
• W4248583983 cites W2052064222 @default.
• W4248583983 cites W2054081131 @default.
• W4248583983 cites W2054380003 @default.
• W4248583983 cites W2055793767 @default.
• W4248583983 cites W2062943152 @default.
• W4248583983 cites W2065777975 @default.
• W4248583983 cites W2070086105 @default.
• W4248583983 cites W2070262065 @default.
• W4248583983 cites W2072877398 @default.
• W4248583983 cites W2079973734 @default.
• W4248583983 cites W2081735313 @default.
• W4248583983 cites W2084591163 @default.
• W4248583983 cites W2084671078 @default.
• W4248583983 cites W2084774766 @default.
• W4248583983 cites W2085165928 @default.
• W4248583983 cites W2086259312 @default.
• W4248583983 cites W2093060652 @default.
• W4248583983 cites W2094108169 @default.
• W4248583983 cites W2095052958 @default.
• W4248583983 cites W2103017827 @default.
• W4248583983 cites W2105996005 @default.
• W4248583983 cites W2113542630 @default.
• W4248583983 cites W2116079297 @default.
• W4248583983 cites W2119041499 @default.
• W4248583983 cites W2119820612 @default.
• W4248583983 cites W2124852855 @default.
• W4248583983 cites W2125014801 @default.
• W4248583983 cites W2125953041 @default.
• W4248583983 cites W2131951074 @default.
• W4248583983 cites W2145090109 @default.
• W4248583983 cites W2158751800 @default.
• W4248583983 cites W2161341147 @default.
• W4248583983 cites W2161381370 @default.
• W4248583983 cites W2168980569 @default.
• W4248583983 cites W2314689571 @default.
• W4248583983 cites W4234523356 @default.
• W4248583983 cites W4240083082 @default.
• W4248583983 cites W4251138558 @default.
• W4248583983 doi "https://doi.org/10.1002/14651858.cd006281.pub2" @default.
• W4248583983 hasPublicationYear "2009" @default.
• W4248583983 type Work @default.
• W4248583983 citedByCount "6" @default.
• W4248583983 countsByYear W42485839832012 @default.
• W4248583983 countsByYear W42485839832014 @default.
• W4248583983 countsByYear W42485839832019 @default.
• W4248583983 crossrefType "reference-entry" @default.
• W4248583983 hasAuthorship W4248583983A5014769151 @default.
• W4248583983 hasAuthorship W4248583983A5047421271 @default.
• W4248583983 hasAuthorship W4248583983A5064268727 @default.
• W4248583983 hasAuthorship W4248583983A5070233617 @default.
• W4248583983 hasAuthorship W4248583983A5083275825 @default.
• W4248583983 hasConcept C114614502 @default.
• W4248583983 hasConcept C126322002 @default.
• W4248583983 hasConcept C141071460 @default.

• next